UNITED STATES DEPARTMENT OF THE
TREASURY
1500 PENNSYLVANIA AVENUE,
NW
WASHINGTON, D.C. 20220
Dear Ladies and
Gentlemen:
The company set forth on the signature page
hereto (the “ Company ”) intends to issue in a
private placement the number of shares of a series of its preferred
stock set forth on Schedule A hereto (the “ Preferred
Shares ”) and a warrant to purchase the number of shares
of a series of its preferred stock set forth on Schedule A hereto
(the “ Warrant ” and, together with the
Preferred Shares, the “ Purchased Securities ”)
and the United States Department of the Treasury (the “
Investor ”) intends to purchase from the Company the
Purchased Securities.
The purpose of this letter agreement is to
confirm the terms and conditions of the purchase by the Investor of
the Purchased Securities. Except to the extent supplemented or
superseded by the terms set forth herein or in the Schedules
hereto, the provisions contained in the Securities Purchase
Agreement – Standard Terms attached hereto as Exhibit A (the
“ Securities Purchase Agreement ”) are
incorporated by reference herein. Terms that are defined in the
Securities Purchase Agreement are used in this letter agreement as
so defined. In the event of any inconsistency between this letter
agreement and the Securities Purchase Agreement, the terms of this
letter agreement shall govern.
Each of the Company and the Investor hereby
confirms its agreement with the other party with respect to the
issuance by the Company of the Purchased Securities and the
purchase by the Investor of the Purchased Securities pursuant to
this letter agreement and the Securities Purchase Agreement on the
terms specified on Schedule A hereto.
This letter agreement (including the Schedules
hereto), the Securities Purchase Agreement (including the Annexes
thereto), the Disclosure Schedules and the Warrant constitute the
entire agreement, and supersede all other prior agreements,
understandings, representations and warranties, both written and
oral, between the parties, with respect to the subject matter
hereof. This letter agreement constitutes the “Letter
Agreement” referred to in the Securities Purchase
Agreement.
This letter agreement may be executed in any
number of separate counterparts, each such counterpart being deemed
to be an original instrument, and all such counterparts will
together constitute the same agreement. Executed signature pages to
this letter agreement may be delivered by facsimile and such
facsimiles will be deemed as sufficient as if actual signature
pages had been delivered.
* * *
In witness whereof, this letter agreement has
been duly executed and delivered by the duly authorized
representatives of the parties hereto as of the date written
below.
UNITED STATES
DEPARTMENT OF THE TREASURY
COMPANY: M&F BANCORP,
INC.
Title: President
and Chief Executive
ADDITIONAL TERMS AND
CONDITIONS
Company
Information :
Name of the
Company: M&F
Bancorp, Inc.
Corporate or
other organizational
form: corporation
Jurisdiction of
Organization: North
Carolina
Appropriate
Federal Banking
Agency:
Federal Deposit Insurance Corporation
Notice
Information: Kim
D.
Saunders with
a copy to:
President and
Chief Executive
Officer Iain
MacSween, Esq.
M & F
Bancorp,
Inc. Brooks,
Pierce, McLendon,
2634 Durham
Chapel Hill
Blvd. Humphrey
& Leonard, L.L.P.
Durham,
NC 27707 P.O.
Box 26000
Terms of the
Purchase:
Series of
Preferred Stock
Purchased: Fixed
Rate Cumulative Perpetual Preferred
Per Share
Liquidation Preference of Preferred
Stock: $1,000
Number of
Shares of Preferred Stock
Purchased: 11,735
Dividend
Payment Dates on the Preferred
Stock: February
15, May 15, August 15, and
November 15 of
each year.
Series of
Warrant Preferred
Stock: Not
Applicable
Number of
Warrant
Shares: 0
Number of Net
Warrant Shares (after net
settlement): 0
Exercise Price
of the
Warrant: Not
Applicable
Purchase
Price: $11,735,000
Closing:
Location of
Closing: Hughes
Hubbard & Reed LLPOne Battery Park Plaza
Time of
Closing: 9:00
a.m. EDST
Date of
Closing: June
26, 2009
Wire
Information for Closing : ABA
Number: XXXXX
Bank: XXXXX
Contact for
Confirmation of Wire
Information: Taylor
Ramirez
Controller
Mechanics and Farmers Bank
09533
-0002-10033-NY02.2690847.9
CAPITALIZATION
Capitalization
Date: May
31, 2009
Total
Authorized: 5,000,000
Subject to warrants, options, convertible
securities,
etc.: 25,200
Reserved for benefit plans and other
issuances: 0
(1)
Remaining authorized but
unissued: 2,943,463
(1)
Shares issued after Capitalization Date
(other
than pursuant to warrants, options,
convertible securities, etc. as set forth
above): 0
Par
value: Not
applicable
Outstanding (by
series):
0
Remaining authorized but
unissued:
0
Holders of
5% or more of any class of capital stock
Primary Address
|
Dr.
Vivian M. Sansom (2) (8.9%)
|
1521
Cross Link Road
|
|
|
|
|
Mrs.
Selena W.
Wheeler (8.0%)
|
2029
Heritage Pines Drive
|
|
|
|
|
North
Carolina Mutual Life Insurance Company (9.2%)
|
411 West
Chapel Hill Street
|
|
|
|
|
Ms. Julia
W. Taylor (3) (10.4%)
|
2029
Heritage Pines Drive
|
|
|
Cary, NC
27519
|
(1) Excludes authorized but unissued shares of
Common Stock reserved for issuance pursuant to 25,200 outstanding
stock options.
|
(2) Pursuant to a Power of Attorney, Dr.
Sansom’s sons, Joseph M. Sansom and James E. Sansom, each
have voting and investment powers over Dr. Sansom’s shares of
common stock.
|
(3) Ms. Taylor serves as attorney-in-fact for Ms.
Wheeler and, as such, has certain voting and investment powers over
these shares. Excluding Mrs. Wheeler’s shares, Ms. Taylor
beneficially owns approximately 2.4% of the outstanding common
stock.
|
SECURITIES PURCHASE
AGREEMENT
EXHIBIT A
(Non-Exchange-Traded QFIs,
excluding S Corps
and Mutual
Organizations)
SECURITIES PURCHASE
AGREEMENT
STANDARD TERMS
Article I
Purchase; Closing
|
1.1
|
|
|
|
1.2
|
|
|
|
1.3
|
|
|
|
|
|
|
|
|
Representations
and Warranties
|
|
|
2.1
|
|
|
|
2.2
|
Representations
and Warranties of the
Company
|
|
|
|
|
|
|
|
|
|
|
3.1
|
Commercially
Reasonable
Efforts
|
|
|
3.2
|
|
|
|
3.3
|
Sufficiency of
Authorized Warrant Preferred Stock; Exchange Listing
|
|
|
3.4
|
Certain
Notifications Until
Closing
|
|
|
3.5
|
Access,
Information and
Confidentiality
|
|
|
|
|
|
|
|
|
|
|
4.1
|
|
|
|
4.2
|
|
|
|
4.3
|
|
|
|
4.4
|
Transfer of
Purchased Securities and Warrant Shares; Restrictions on
Exercise
|
|
|
|
|
|
|
4.5
|
|
|
|
4.6
|
|
|
|
4.7
|
Restriction on
Dividends and
Repurchases
|
|
|
4.8
|
|
|
|
4.9
|
Related Party
Transactions
|
|
|
4.10
|
Bank and Thrift
Holding Company
Status
|
|
|
4.11
|
|
|
|
09533 1-
-10033-NY02.2690847.9-ii-
|
Article V
Miscellaneous
|
5.1
|
|
|
|
5.2
|
Survival of
Representations and
Warranties
|
|
|
5.3
|
|
|
|
5.4
|
|
|
|
5.5
|
Governing
Law: Submission to Jurisdiction, Etc .
|
|
|
5.6
|
|
|
|
5.7
|
|
|
|
5.8
|
|
|
|
5.9
|
|
|
|
5.10
|
No Third Party
Beneficiaries
|
|
|
09533 1-
-10033-NY02.2690847.9-ii-
|
ANNEX A: FORM
OF CERTIFICATE OF DESIGNATIONS FOR PREFERRED STOCK
|
ANNEX B: FORM
OF CERTIFICATE OF DESIGNATIONS FOR WARRANT PREFERRED
STOCK
|
ANNEX C: FORM
OF WAIVER ANNEX D: FORM OF OPINION ANNEX E: FORM OF
WARRANT
|
09533
-0002-10033-NY02.2690847.9-iv-
|
INDEX OF
DEFINED TERMS
|
|
|
|
|
Affiliate
|
5.7(b)
|
|
|
Agreement
|
Recitals
|
|
|
Appropriate
Federal Banking Agency
|
2.2(s)
|
|
|
Bank Holding
Company
|
4.10
|
|
|
Bankruptcy
Exceptions
|
2.2(d)
|
|
|
Benefit
Plans
|
1
.2(d)(iv)
|
|
|
Board of
Directors
|
2.2(f)
|
|
|
Business
Combination
|
5.8
|
|
|
business
day
|
1.3
|
|
|
Capitalization
Date
|
2.2(b)
|
|
|
Certificates of
Designations
|
1.2(d)
(iii)
|
|
|
Charter
|
1
.2(d)(iii)
|
|
|
Closing
|
1.2(a)
|
|
|
Closing
Date
|
1.2(a)
|
|
|
Code
|
2.2(n)
|
|
|
Common
Stock
|
2.2(b)
|
|
|
Company
|
Recitals
|
|
|
Company
Financial Statements
|
2.2(h)
|
|
|
Company
Material Adverse Effect
|
2.1(b)
|
|
|
Company
Reports
|
2.2(i)(i)
|
|
|
Company
Subsidiary; Company Subsidiaries
|
2.2(e)(ii)
|
|
|
control;
controlled by; under common control with
|
5.7(b)
|
|
|
Controlled
Group
|
2.2(n)
|
|
|
CPP
|
Recitals
|
|
|
Disclosure
Schedule
|
2.1(a)
|
|
|
EESA
|
1.2(d)(iv)
|
|
|
ERISA
|
2.2(n)
|
|
|
Exchange
Act
|
4.4
|
|
|
Federal
Reserve
|
4.10
|
|
|
GAAP
|
2.1(b)
|
|
|
Governmental
Entities
|
1.2(c)
|
|
|
Holder
|
4.5(l)(i)
|
|
|
Holders’
Counsel
|
4.5(l)(ii)
|
|
|
Indemnitee
|
4.
5(h)(i)
|
|
|
Information
|
3.5(c)
|
|
|
Investor
|
Recitals
|
|
|
Junior
Stock
|
4.7(f)
|
|
|
knowledge of
the Company; Company’s knowledge
|
5.7(c)
|
|
|
Letter
Agreement
|
Recitals
|
|
|
officers
|
5.7(c)
|
|
|
Parity
Stock
|
4.7(f)
|
|
|
|
|
|
|
09533
-0002-10033-NY02.2690847.9-iv-
|
|
Pending
Underwritten Offering
|
4.5(m)
|
|
Permitted
Repurchases
|
4.7(c)
|
|
Piggyback
Registration
|
4.5(b)(iv)
|
|
Plan
|
2.2(n)
|
|
Preferred
Shares
|
Recitals
|
|
Preferred
Stock
|
Recitals
|
|
Previously
Disclosed
|
2.1(c)
|
|
Proprietary
Rights
|
2.2(u)
|
|
Purchase
|
Recitals
|
|
Purchase
Price
|
1.1
|
|
Purchased
Securities
|
Recitals
|
|
register;
registered; registration
|
4.5(l)(iii)
|
|
Registrable
Securities
|
4.5(l)(iv)
|
|
Registration
Expenses
|
4.5(l)(v)
|
|
Regulatory
Agreement
|
2.2(s)
|
|
Rule 144; Rule
144A; Rule 159A; Rule 405; Rule 415
|
4.5(l)(vi)
|
|
Savings and
Loan Holding Company
|
4.10
|
|
Schedules
|
Recitals
|
|
SEC
|
2.2(k)
|
|
Securities
Act
|
2.2(a)
|
|
Selling
Expenses
|
4.5(l)(vii)
|
|
Senior
Executive Officers
|
4.8
|
|
Shelf
Registration Statement
|
4.5(b)(ii)
|
|
Signing
Date
|
2.1(b)
|
|
Special
Registration
|
4.5(j)
|
|
subsidiary
|
5.7(a)
|
|
Tax;
Taxes
|
2.2(o)
|
|
Transfer
|
4.4
|
|
Warrant
|
Recitals
|
|
Warrant
Preferred Stock
|
Recitals
|
|
Warrant
Shares
|
2.2(d)
|
|
09533
-0002-10033-NY02.2690847.9-iv-
|
SECURITIES PURCHASE AGREEMENT
– STANDARD TERMS
Recitals:
WHEREAS, the United States Department of the
Treasury (the “ Investor ”) may from time to
time agree to purchase shares of preferred stock and warrants from
eligible financial institutions which elect to participate in the
Troubled Asset Relief Program Capital Purchase Program (“
CPP ”);
WHEREAS, an eligible financial institution
electing to participate in the CPP and issue securities to the
Investor (referred to herein as the “ Company ”)
shall enter into a letter agreement (the “ Letter
Agreement ”) with the Investor which incorporates this
Securities Purchase Agreement – Standard Terms;
WHEREAS, the Company agrees to expand the flow
of credit to U.S. consumers and businesses on competitive terms to
promote the sustained growth and vitality of the U.S.
economy;
WHEREAS, the Company agrees to work diligently,
under existing programs, to modify the terms of residential
mortgages as appropriate to strengthen the health of the U.S.
housing market;
WHEREAS, the Company intends to issue in a
private placement the number of shares of the series of its
Preferred Stock (“ Preferred Stock ”) set forth
on Schedule A to the Letter Agreement (the “
Preferred Shares ”) and a warrant to purchase the
number of shares of the series of its Preferred Stock (“
Warrant Preferred Stock ”) set forth on Schedule
A to the Letter Agreement (the “ Warrant ”
and, together with the Preferred Shares, the “ Purchased
Securities ”) and the Investor intends to purchase (the
“ Purchase ”) from the Company the Purchased
Securities; and
WHEREAS, the Purchase will be governed by this
Securities Purchase Agreement – Standard Terms and the Letter
Agreement, including the schedules thereto (the “
Schedules ”), specifying additional terms of the
Purchase. This Securities Purchase Agreement – Standard Terms
(including the Annexes hereto) and the Letter Agreement (including
the Schedules thereto) are together referred to as this
“Agreement”. All references in this Securities Purchase
Agreement – Standard Terms to “Schedules” are to
the Schedules attached to the Letter Agreement.
NOW, THEREFORE , in consideration of the premises, and of the
representations, warranties, covenants and agreements set forth
herein, the parties agree as follows:
Article I
Purchase; Closing
1.1
Purchase. On the terms and subject to the conditions set
forth in this Agreement,
the Company
agrees to sell to the Investor, and the Investor agrees to purchase
from the Company, at the Closing (as hereinafter defined), the
Purchased Securities for the price set forth on Schedule A
(the “ Purchase Price ”).
09533
1--10033-NY02.2690847.9
(a) On the terms and
subject to the conditions set forth in this Agreement, the closing
of the Purchase (the “ Closing ”) will take
place at the location specified in Schedule A, at the time
and on the date set forth in Schedule A or as soon as
practicable thereafter, or at such other place, time and date as
shall be agreed between the Company and the Investor. The time and
date on which the Closing occurs is referred to in this Agreement
as the “ Closing Date ”.
(b) Subject to the
fulfillment or waiver of the conditions to the Closing in this
Section 1.2, at the Closing the Company will deliver the Preferred
Shares and the Warrant, in each case as evidenced by one or more
certificates dated the Closing Date and bearing appropriate legends
as hereinafter provided for, in exchange for payment in full of the
Purchase Price by wire transfer of immediately available United
States funds to a bank account designated by the Company on
Schedule A.
(c) The respective
obligations of each of the Investor and the Company to consummate
the Purchase are subject to the fulfillment (or waiver by the
Investor and the Company, as applicable) prior to the Closing of
the conditions that (i) any approvals or authorizations of all
United States and other governmental, regulatory or judicial
authorities (collectively, “ Governmental Entities
”) required for the consummation of the Purchase shall have
been obtained or made in form and substance reasonably satisfactory
to each party and shall be in full force and effect and all waiting
periods required by United States and other applicable law, if any,
shall have expired and (ii) no provision of any applicable United
States or other law and no judgment, injunction, order or decree of
any Governmental Entity shall prohibit the purchase and sale of the
Purchased Securities as contemplated by this Agreement.
(d) The obligation of
the Investor to consummate the Purchase is also subject to the
fulfillment (or waiver by the Investor) at or prior to the Closing
of each of the following conditions:
(i)(A) the
representations and warranties of the Company set forth in
(x)
Section 2.2(g)
of this Agreement shall be true and correct in all respects as
though made on and as of the Closing Date, (y) Sections 2.2(a)
through (f) shall be true and correct in all material respects as
though made on and as of the Closing Date (other than
representations
and warranties that by their terms speak as of another date, which
representations and warranties shall be true and correct in all
material respects as of such other date) and (z) Sections 2.2(h)
through (v) (disregarding all qualifications or limitations set
forth in such representations and warranties as to
“materiality”, “Company Material Adverse
Effect” and words of similar import) shall be true and
correct as though made on and as of the Closing Date (other than
representations and warranties that by their terms speak as of
another date, which representations and warranties shall be true
and correct as of such other date), except to the extent that the
failure of such representations and warranties referred to in this
Section 1 .2(d)(i)(A)(z) to be so true and correct, individually or
in the aggregate, does not have and would not reasonably be
expected to have a Company Material Adverse Effect and (B) the
Company shall have
09533
-0002-10033-NY02.2690847.9-3-
performed in
all material respects all obligations required to be performed by
it under this Agreement at or prior to the Closing;
(ii) the Investor shall
have received a certificate signed on behalf of the Company by a
senior executive officer certifying to the effect that the
conditions set forth in Section 1 .2(d)(i) have been
satisfied;
(iii) the Company shall
have duly adopted and filed with the Secretary of State of its
jurisdiction of organization or other applicable Governmental
Entity the amendments to its certificate or articles of
incorporation, articles of association, or similar organizational
document (“ Charter ”) in substantially the
forms attached hereto as Annex A and Annex B (the
“ Certificates of Designations ”) and such
filing shall have been accepted;
(iv) (A) the Company
shall have effected such changes to its compensation, bonus,
incentive and other benefit plans, arrangements and agreements
(including golden parachute, severance and employment agreements)
(collectively, “ Benefit Plans ”) with respect
to its Senior Executive Officers (and to the extent necessary for
such changes to be legally enforceable, each of its Senior
Executive Officers shall have duly consented in writing to such
changes), as may be necessary, during the period that the Investor
owns any debt or equity securities of the Company acquired pursuant
to this Agreement or the Warrant, in order to comply with Section
111(b) of the Emergency Economic Stabilization Act of 2008 (“
EESA ”) as implemented by guidance or regulation
thereunder that has been issued and is in effect as of the Closing
Date, and (B) the Investor shall have received a certificate signed
on behalf of the Company by a senior executive officer certifying
to the effect that the condition set forth in Section 1
.2(d)(iv)(A) has been satisfied;
(v) each of the
Company’s Senior Executive Officers shall have delivered to
the Investor a written waiver in the form attached hereto as
Annex C releasing the Investor from any claims that such
Senior Executive Officers may otherwise have as a result of the
issuance, on or prior to the Closing Date, of any regulations which
require the modification of, and the agreement of the Company
hereunder to modify, the terms of any Benefit Plans with respect to
its Senior Executive Officers to eliminate any provisions of such
Benefit Plans that would not be in compliance with the requirements
of Section 111(b) of the EESA as implemented by guidance or
regulation thereunder that has been issued and is in effect as of
the Closing Date;
(vi) the Company shall
have delivered to the Investor a written opinion from counsel to
the Company (which may be internal counsel), addressed to the
Investor and dated as of the Closing Date, in substantially the
form attached hereto as Annex D;
(vii) the Company shall
have delivered certificates in proper form or, with the prior
consent of the Investor, evidence of shares in book-entry form,
evidencing the Preferred Shares to Investor or its designee(s);
and
09533
-0002-10033-NY02.2690847.9-3-
(viii) the Company shall have duly executed the
Warrant in substantially the form attached hereto as Annex E
and delivered such executed Warrant to the Investor or its
designee(s).
1.3
Interpretation. When a reference is made in this Agreement
to “Recitals,”
“Articles,” “Sections,”
or “Annexes” such reference shall be to a Recital,
Article or Section of, or Annex to, this Securities Purchase
Agreement – Standard Terms, and a reference to
“Schedules” shall be to a Schedule to the Letter
Agreement, in each case, unless otherwise indicated. The terms
defined in the singular have a comparable meaning when used in the
plural, and vice versa. References to “herein”,
“hereof”, “hereunder” and the like refer to
this Agreement as a whole and not to any particular section or
provision, unless the context requires otherwise. The table of
contents and headings contained in this Agreement are for reference
purposes only and are not part of this Agreement. Whenever the
words “include,” "includes” or
“including” are used in this Agreement, they shall be
deemed followed by the words “without limitation.” No
rule of construction against the draftsperson shall be applied in
connection with the interpretation or enforcement of this
Agreement, as this Agreement is the product of negotiation between
sophisticated parties advised by counsel. All references to
“$” or “dollars” mean the lawful currency
of the United States of America. Except as expressly stated in this
Agreement, all references to any statute, rule or regulation are to
the statute, rule or regulation as amended, modified, supplemented
or replaced from time to time (and, in the case of statutes,
include any rules and regulations promulgated under the statute)
and to any section of any statute, rule or regulation include any
successor to the section. References to a “ business
day ” shall mean any day except Saturday, Sunday and any
day on which banking institutions in the State of New York
generally are authorized or required by law or other governmental
actions to close.
Article II
Representations and
Warranties
(a) On or prior to the
Signing Date, the Company delivered to the Investor a schedule
(“ Disclosure Schedule ”) setting forth, among
other things, items the disclosure of which is necessary or
appropriate either in response to an express disclosure requirement
contained in a provision hereof or as an exception to one or more
representations or warranties contained in Section 2.2.
(b) “ Company
Material Adverse Effect ” means a material adverse effect
on (i) the business, results of operation or financial condition of
the Company and its consolidated subsidiaries taken as a whole;
provided , however , that Company Material Adverse
Effect shall not be deemed to include the effects of (A) changes
after the date of the Letter Agreement (the “ Signing
Date ”) in general business, economic or market
conditions (including changes generally in prevailing interest
rates, credit availability and liquidity, currency exchange rates
and price levels or trading volumes in the United States or foreign
securities or credit markets), or any outbreak or escalation of
hostilities, declared or undeclared acts of war or terrorism,
in
|
09533 1-
-10033-NY02.2690847.9-5-
|
each case
generally affecting the industries in which the Company and its
subsidiaries operate, (B) changes or proposed changes after the
Signing Date in generally accepted accounting principles in the
United States (“ GAAP ”) or regulatory
accounting requirements, or authoritative interpretations thereof,
or (C) changes or proposed changes after the Signing Date in
securities, banking and other laws of general applicability or
related policies or interpretations of Governmental Entities (in
the case of each of these clauses (A), (B) and (C), other than
changes or occurrences to the extent that such changes or
occurrences have or would reasonably be expected to have a
materially disproportionate adverse effect on the Company and its
consolidated subsidiaries taken as a whole relative to comparable
U.S. banking or financial services organizations); or (ii) the
ability of the Company to consummate the Purchase and other
transactions contemplated by this Agreement and the Warrant and
perform its obligations hereunder or thereunder on a timely
basis.
(c) “
Previously Disclosed ” means information set forth on
the Disclosure Schedule, provided, however, that disclosure in any
section of such Disclosure Schedule shall apply only to the
indicated section of this Agreement except to the extent that it is
reasonably apparent from the face of such disclosure that such
disclosure is relevant to another section of this
Agreement.
2.2
Representations and Warranties of the Company. Except as
Previously Disclosed,
the Company
represents and warrants to the Investor that as of the Signing Date
and as of the Closing Date (or such other date specified
herein):
(a)
Organization, Authority and Significant Subsidiaries. The
Company has been duly incorporated and is validly existing and in
good standing under the laws of its jurisdiction of organization,
with the necessary power and authority to own its properties and
conduct its business in all material respects as currently
conducted, and except as has not, individually or in the aggregate,
had and would not reasonably be expected to have a Company Material
Adverse Effect, has been duly qualified as a foreign corporation
for the transaction of business and is in good standing under the
laws of each other jurisdiction in which it owns or leases
properties or conducts any business so as to require such
qualification; each subsidiary of the Company that would be
considered a “significant subsidiary” within the
meaning of Rule 1-02(w) of Regulation S-X under the Securities Act
of 1933 (the “ Securities Act ”), has been duly
organized and is validly existing in good standing under the laws
of its jurisdiction of organization. The Charter and bylaws of the
Company, copies of which have been provided to the Investor prior
to the Signing Date, are true, complete and correct copies of such
documents as in full force and effect as of the Signing
Date.
(b)
Capitalization. The authorized capital stock of the Company,
and the outstanding capital stock of the Company (including
securities convertible into, or exercisable or exchangeable for,
capital stock of the Company) as of the most recent fiscal
month-end preceding the Signing Date (the “ Capitalization
Date ”) is set forth on Schedule B. The
outstanding shares of capital stock of the Company have been duly
authorized and are validly issued and outstanding, fully paid and
nonassessable, and subject to no preemptive rights (and were not
issued in violation of any preemptive rights). As of the Signing
Date, the Company does not have outstanding any securities or other
obligations providing the holder the right to
|
09533 1-
-10033-NY02.2690847.9-5-
|
acquire its
Common Stock (“ Common Stock ”) that is not
reserved for issuance as specified on Schedule B, and the
Company has not made any other commitment to authorize, issue or
sell any Common Stock. Since the Capitalization Date, the Company
has not issued any shares of Common Stock, other than (i) shares
issued upon the exercise of stock options or delivered under other
equity-based awards or other convertible securities or warrants
which were issued and outstanding on the Capitalization Date and
disclosed on Schedule B and (ii) shares disclosed on
Schedule B. Each holder of 5% or more of any class of
capital stock of the Company and such holder’s primary
address are set forth on Schedule B.
(c)
Preferred Shares. The Preferred Shares have been duly and
validly authorized, and, when issued and delivered pursuant to this
Agreement, such Preferred Shares will be duly and validly issued
and fully paid and non-assessable, will not be issued in violation
of any preemptive rights, and will rank pari passu with or
senior to all other series or classes of Preferred Stock, whether
or not issued or outstanding, with respect to the payment of
dividends and the distribution of assets in the event of any
dissolution, liquidation or winding up of the Company.
(d)
The
Warrant and Warrant Shares. The Warrant has been duly
authorized and, when executed and delivered as contemplated hereby,
will constitute a valid and legally binding obligation of the
Company enforceable against the Company in accordance with its
terms, except as the same may be limited by applicable bankruptcy,
insolvency, reorganization, moratorium or similar laws affecting
the enforcement of creditors’ rights generally and general
equitable principles, regardless of whether such enforceability is
considered in a proceeding at law or in equity (“
Bankruptcy Exceptions ”). The shares of Warrant
Preferred Stock issuable upon exercise of the Warrant (the “
Warrant Shares ”) have been duly authorized and
reserved for issuance upon exercise of the Warrant and when so
issued in accordance with the terms of the Warrant will be validly
issued, fully paid and non-assessable, and will rank pari
passu with or senior to all other series or classes of
Preferred Stock, whether or not issued or outstanding, with respect
to the payment of dividends and the distribution of assets in the
event of any dissolution, liquidation or winding up of the
Company.
(e)
Authorization, Enforceability.
(i)The Company
has the corporate power and authority to execute and
deliver this
Agreement and the Warrant and to carry out its obligations
hereunder and thereunder (which includes the issuance of the
Preferred Shares, Warrant and Warrant Shares). The execution,
delivery and performance by the Company of this Agreement and the
Warrant and the consummation of the transactions contemplated
hereby and thereby have been duly authorized by all necessary
corporate action on the part of the Company and its stockholders,
and no further approval or authorization is required on the part of
the Company. This Agreement is a valid and binding obligation of
the Company enforceable against the Company in accordance with its
terms, subject to the Bankruptcy Exceptions.
09533
-0002-10033-NY02.2690847.9-7-
(ii) The execution,
delivery and performance by the Company of this Agreement and the
Warrant and the consummation of the transactions contemplated
hereby and thereby and compliance by the Company with the
provisions hereof and thereof, will not (A) violate, conflict with,
or result in a breach of any provision of, or constitute a default
(or an event which, with notice or lapse of time or both, would
constitute a default) under, or result in the termination of, or
accelerate the performance required by, or result in a right of
termination or acceleration of, or result in the creation of, any
lien, security interest, charge or encumbrance upon any of the
properties or assets of the Company or any subsidiary of the
Company (each a “ Company Subsidiary ” and,
collectively, the “ Company Subsidiaries ”)
under any of the terms, conditions or provisions of (i) its
organizational documents or (ii) any note, bond, mortgage,
indenture, deed of trust, license, lease, agreement or other
instrument or obligation to which the Company or any Company
Subsidiary is a party or by which it or any Company Subsidiary may
be bound, or to which the Company or any Company Subsidiary or any
of the properties or assets of the Company or any Company
Subsidiary may be subject, or (B) subject to compliance with the
statutes and regulations referred to in the next paragraph, violate
any statute, rule or regulation or any judgment, ruling, order,
writ, injunction or decree applicable to the Company or any Company
Subsidiary or any of their respective properties or assets except,
in the case of clauses (A)(ii) and (B), for those occurrences that,
individually or in the aggregate, have not had and would not
reasonably be expected to have a Company Material Adverse
Effect.
(iii) Other than the
filing of the Certificates of Designations with the Secretary of
State of its jurisdiction of organization or other applicable
Governmental Entity, such filings and approvals as are required to
be made or obtained under any state “blue sky” laws and
such as have been made or obtained, no notice to, filing with,
exemption or review by, or authorization, consent or approval of,
any Governmental Entity is required to be made or obtained by the
Company in connection with the consummation by the Company of the
Purchase except for any such notices, filings, exemptions, reviews,
authorizations, consents and approvals the failure of which to make
or obtain would not, individually or in the aggregate, reasonably
be expected to have a Company Material Adverse Effect.
(f)
Anti-takeover Provisions and Rights Plan. The Board of
Directors of the Company (the “ Board of Directors
”) has taken all necessary action to ensure that the
transactions contemplated by this Agreement and the Warrant and the
consummation of the transactions contemplated hereby and thereby,
including the exercise of the Warrant in accordance with its terms,
will be exempt from any anti-takeover or similar provisions of the
Company’s Charter and bylaws, and any other provisions of any
applicable “moratorium”, “control share”,
“fair price”, “interested stockholder” or
other anti-takeover laws and regulations of any
jurisdiction.
(g)
No
Company Material Adverse Effect. Since the last day of the last
completed fiscal period for which financial statements are included
in the Company Financial Statements (as defined below), no fact,
circumstance, event, change, occurrence, condition or
development
09533
-0002-10033-NY02.2690847.9-7-
has occurred
that, individually or in the aggregate, has had or would reasonably
be expected to have a Company Material Adverse Effect.
(h)
Company Financial Statements. The Company has Previously
Disclosed each of the consolidated financial statements of the
Company and its consolidated subsidiaries for each of the last
three completed fiscal years of the Company (which shall be audited
to the extent audited financial statements are available prior to
the Signing Date) and each completed quarterly period since the
last completed fiscal year (collectively the “ Company
Financial Statements ”). The Company Financial Statements
present fairly in all material respects the consolidated financial
position of the Company and its consolidated subsidiaries as of the
dates indicated therein and the consolidated results of their
operations for the periods specified therein; and except as stated
therein, such financial statements (A) were prepared in conformity
with GAAP applied on a consistent basis (except as may be noted
therein) and (B) have been prepared from, and are in accordance
with, the books and records of the Company and the Company
Subsidiaries.
(i) Since December 31,
2006, the Company and each Company Subsidiary has filed all
reports, registrations, documents, filings, statements and
submissions, together with any amendments thereto, that it was
required to file with any Governmental Entity (the foregoing,
collectively, the “ Company Reports ”) and has
paid all fees and assessments due and payable in connection
therewith, except, in each case, as would not, individually or in
the aggregate, reasonably be expected to have a Company Material
Adverse Effect. As of their respective dates of filing, the Company
Reports complied in all material respects with all statutes and
applicable rules and regulations of the applicable Governmental
Entities.
(ii) The records,
systems, controls, data and information of the Company and the
Company Subsidiaries are recorded, stored, maintained and operated
under means (including any electronic, mechanical or photographic
process, whether computerized or not) that are under the exclusive
ownership and direct control of the Company or the Company
Subsidiaries or their accountants (including all means of access
thereto and therefrom), except for any non-exclusive ownership and
non-direct control that would not reasonably be expected to have a
material adverse effect on the system of internal accounting
controls described below in this Section 2.2(i)(ii). The Company
(A) has implemented and maintains adequate disclosure controls and
procedures to ensure that material information relating to the
Company, including the consolidated Company Subsidiaries, is made
known to the chief executive officer and the chief financial
officer of the Company by others within those entities, and (B) has
disclosed, based on its most recent evaluation prior to the Signing
Date, to the Company’s outside auditors and the audit
committee of the Board of Directors (x) any significant
deficiencies and material weaknesses in the design or operation of
internal controls that are reasonably likely to adversely affect
the Company’s ability to record, process, summarize and
report financial information and (y) any fraud, whether or not
material, that involves management or
09533 1-
-10033-NY02.2690847.9-9-
other employees
who have a significant role in the Company’s internal
controls over financial reporting.
(j)
No
Undisclosed Liabilities. Neither the Company nor any of the
Company Subsidiaries has any liabilities or obligations of any
nature (absolute, accrued, contingent or otherwise) which are not
properly reflected or reserved against in the Company Financial
Statements to the extent required to be so reflected or reserved
against in accordance with GAAP, except for (A) liabilities that
have arisen since the last fiscal year end in the ordinary and
usual course of business and consistent with past practice and (B)
liabilities that, individually or in the aggregate, have not had
and would not reasonably be expected to have a Company Material
Adverse Effect.
(k)
Offering of Securities. Neither the Company nor any person
acting on its behalf has taken any action (including any offering
of any securities of the Company under circumstances which would
require the integration of such offering with the offering of any
of the Purchased Securities under the Securities Act, and the rules
and regulations of the Securities and Exchange Commission (the
“ SEC ”) promulgated thereunder), which might
subject the offering, issuance or sale of any of the Purchased
Securities to Investor pursuant to this Agreement to the
registration requirements of the Securities Act.
(l)
Litigation and Other Proceedings. Except (i) as set forth on
Schedule C or (ii) as would not, individually or in the
aggregate, reasonably be expected to have a Company Material
Adverse Effect, there is no (A) pending or, to the knowledge of the
Company, threatened, claim, action, suit, investigation or
proceeding, against the Company or any Company Subsidiary or to
which any of their assets are subject nor is the Company or any
Company Subsidiary subject to any order, judgment or decree or (B)
unresolved violation, criticism or exception by any Governmental
Entity with respect to any report or relating to any examinations
or inspections of the Company or any Company
Subsidiaries.
(m)
Compliance with Laws. Except as would not, individually or
in the aggregate, reasonably be expected to have a Company Material
Adverse Effect, the Company and the Company Subsidiaries have all
permits, licenses, franchises, authorizations, orders and approvals
of, and have made all filings, applications and registrations with,
Governmental Entities that are required in order to permit them to
own or lease their properties and assets and to carry on their
business as presently conducted and that are material to the
business of the Company or such Company Subsidiary. Except as set
forth on Schedule D, the Company and the Company
Subsidiaries have complied in all respects and are not in default
or violation of, and none of them is, to the knowledge of the
Company, under investigation with respect to or, to the knowledge
of the Company, have been threatened to be charged with or given
notice of any violation of, any applicable domestic (federal, state
or local) or foreign law, statute, ordinance, license, rule,
regulation, policy or guideline, order, demand, writ, injunction,
decree or judgment of any Governmental Entity, other than such
noncompliance, defaults or violations that would not, individually
or in the aggregate, reasonably be expected to have a Company
Material Adverse Effect. Except for statutory or regulatory
restrictions of general application or as set forth on Schedule
D, no Governmental Entity has placed any restriction on the
business or properties of
09533 1-
-10033-NY02.2690847.9-9-
the Company or
any Company Subsidiary that would, individually or in the
aggregate, reasonably be expected to have a Company Material
Adverse Effect.
(n)
Employee Benefit Matters. Except as would not reasonably be
expected to have, either individually or in the aggregate, a
Company Material Adverse Effect: (A) each “employee benefit
plan” (within the meaning of Section 3(3) of the Employee
Retirement Income Security Act of 1974, as amended (“
ERISA ”)) providing benefits to any current or former
employee, officer or director of the Company or any member of its
“ Controlled Group ” (defined as any
organization which is a member of a controlled group of
corporations within the meaning of Section 414 of the Internal
Revenue Code of 1986, as amended (the “ Code ”))
that is sponsored, maintained or contributed to by the Company or
any member of its Controlled Group and for which the Company or any
member of its Controlled Group would have any liability, whether
actual or contingent (each, a “ Plan ”) has been
maintained in compliance with its terms and with the requirements
of all applicable statutes, rules and regulations, including ERISA
and the Code; (B) with respect to each Plan subject to Title IV of
ERISA (including, for purposes of this clause (B), any plan subject
to Title IV of ERISA that the Company or any member of its
Controlled Group previously maintained or contributed to in the six
years prior to the Signing Date), (1) no “reportable
event” (within the meaning of Section 4043(c) of ERISA),
other than a reportable event for which the notice period referred
to in Section 4043(c) of ERISA has been waived, has occurred in the
three years prior to the Signing Date or is reasonably expected to
occur, (2) no “accumulated funding deficiency” (within
the meaning of Section 302 of ERISA or Section 412 of the Code),
whether or not waived, has occurred in the three years prior to the
Signing Date or is reasonably expected to occur, (3) the fair
market value of the assets under each Plan exceeds the present
value of all benefits accrued under such Plan (determined based on
the assumptions used to fund such Plan) and (4) neither the Company
nor any member of its Controlled Group has incurred in the six
years prior to the Signing Date, or reasonably expects to incur,
any liability under Title IV of ERISA (other than contributions to
the Plan or premiums to the PBGC in the ordinary course and without
default) in respect of a Plan (including any Plan that is a
“multiemployer plan”, within the meaning of Section
4001(c)(3) of ERISA); and (C) each Plan that is intended to be
qualified under Section 401(a) of the Code has received a favorable
determination letter from the Internal Revenue Service with respect
to its qualified status that has not been revoked, or such a
determination letter has been timely applied for but not received
by the Signing Date, and nothing has occurred, whether by action or
by failure to act, which could reasonably be expected to cause the
loss, revocation or denial of such qualified status or favorable
determination letter.
(o)
Taxes. Except as would not, individually or in the
aggregate, reasonably be expected to have a Company Material
Adverse Effect, (i) the Company and the Company Subsidiaries have
filed all federal, state, local and foreign income and franchise
Tax returns required to be filed through the Signing Date, subject
to permitted extensions, and have paid all Taxes due thereon, and
(ii) no Tax deficiency has been determined adversely to the Company
or any of the Company Subsidiaries, nor does the Company have any
knowledge of any Tax deficiencies. “ Tax ” or
“ Taxes ” means any federal, state, local or
foreign income, gross receipts, property, sales, use, license,
excise, franchise, employment, payroll, withholding, alternative or
add on minimum, ad valorem, transfer or excise tax, or any other
tax, custom, duty,
governmental
fee or other like assessment or charge of any kind whatsoever,
together with any interest or penalty, imposed by any Governmental
Entity.
(p)
Properties and Leases. Except as would not, individually or
in the aggregate,
reasonably be
expected to have a Company Material Adverse Effect, the Company and
the Company Subsidiaries have good and marketable title to all real
properties and all other properties and assets owned by them, in
each case free from liens, encumbrances, claims and defects that
would affect the value thereof or interfere with the use made or to
be made thereof by them. Except as would not, individually or in
the aggregate, reasonably be expected to have a Company Material
Adverse Effect, the Company and the Company Subsidiaries hold all
leased real or personal property under valid and enforceable leases
with no exceptions that would interfere with the use made or to be
made thereof by them.
(q)
Environmental Liability. Except as would not, individually
or in the aggregate,
reasonably be
expected to have a Company Material Adverse Effect:
(i) there is no legal,
administrative, or other proceeding, claim or action of any nature
seeking to impose, or that would reasonably be expected to result
in the imposition of, on the Company or any Company Subsidiary, any
liability relating to the release of hazardous substances as
defined under any local, state or federal environmental statute,
regulation or ordinance, including the Comprehensive Environmental
Response, Compensation and Liability Act of 1980, pending or, to
the Company’s knowledge, threatened against the Company or
any Company Subsidiary;
(ii) to the
Company’s knowledge, there is no reasonable basis for any
such proceeding, claim or action; and
(iii) neither the
Company nor any Company Subsidiary is subject to any agreement,
order, judgment or decree by or with any court, Governmental Entity
or third party imposing any such environmental
liability.
(r) Risk
Management Instruments. Except as would not, individually or in
the
aggregate,
reasonably be expected to have a Company Material Adverse Effect,
all derivative instruments, including, swaps, caps, floors and
option agreements, whether entered into for the Company’s own
account, or for the account of one or more of the Company
Subsidiaries or its or their customers, were entered into (i) only
in the ordinary course of business, (ii) in accordance with prudent
practices and in all material respects with all applicable laws,
rules, regulations and regulatory policies and (iii) with
counterparties believed to be financially responsible at the time;
and each of such instruments constitutes the valid and legally
binding obligation of the Company or one of the Company
Subsidiaries, enforceable in accordance with its terms, except as
may be limited by the Bankruptcy Exceptions. Neither the Company or
the Company Subsidiaries, nor, to the knowledge of the Company, any
other party thereto, is in breach of any of its obligations under
any such agreement or arrangement other than such breaches that
would not, individually or in the aggregate, reasonably be expected
to have a Company Material Adverse Effect.
09533
-0002-10033-NY02.2690847.9-11-
(s)
Agreements with Regulatory Agencies. Except as set forth on
Schedule E, neither the Company nor any Company Subsidiary
is subject to any material cease-and-desist or other similar order
or enforcement action issued by, or is a party to any material
written agreement, consent agreement or memorandum of understanding
with, or is a party to any commitment letter or similar undertaking
to, or is subject to any capital directive by, or since December
31, 2006, has adopted any board resolutions at the request of, any
Governmental Entity (other than the Appropriate Federal Banking
Agencies with jurisdiction over the Company and the Company
Subsidiaries) that currently restricts in any material respect the
conduct of its business or that in any material manner relates to
its capital adequacy, its liquidity and funding policies and
practices, its ability to pay dividends, its credit, risk
management or compliance policies or procedures, its internal
controls, its management or its operations or business (each item
in this sentence, a “ Regulatory Agreement ”),
nor has the Company or any Company Subsidiary been advised since
December 31, 2006 by any such Governmental Entity that it is
considering issuing, initiating, ordering, or requesting any such
Regulatory Agreement. The Company and each Company Subsidiary are
in compliance in all material respects with each Regulatory
Agreement to which it is party or subject, and neither the Company
nor any Company Subsidiary has received any notice from any
Governmental Entity indicating that either the Company or any
Company Subsidiary is not in compliance in all material respects
with any such Regulatory Agreement. " Appropriate Federal
Banking Agency " means the “appropriate Federal banking
agency” with respect to the Company or such Company
Subsidiaries, as applicable, as defined in Section 3(q) of the
Federal Deposit Insurance Act (12 U.S.C. Section
1813(q)).
(t)
Insurance. The Company and the Company Subsidiaries are
insured with reputable insurers against such risks and in such
amounts as the management of the Company reasonably has determined
to be prudent and consistent with industry practice. The Company
and the Company Subsidiaries are in material compliance with their
insurance policies and are not in default under any of the material
terms thereof, each such policy is outstanding and in full force
and effect, all premiums and other payments due under any material
policy have been paid, and all claims thereunder have been filed in
due and timely fashion, except, in each case, as would not,
individually or in the aggregate, reasonably be expected to have a
Company Material Adverse Effect.
(u)
Intellectual Property. Except as would not, individually or
in the aggregate, reasonably be expected to have a Company Material
Adverse Effect, (i) the Company and each Company Subsidiary owns or
otherwise has the right to use, all intellectual property rights,
including all trademarks, trade dress, trade names, service marks,
domain names, patents, inventions, trade secrets, know-how, works
of authorship and copyrights therein, that are used in the conduct
of their existing businesses and all rights relating to the plans,
design and specifications of any of its branch facilities (“
Proprietary Rights ”) free and clear of all liens and
any claims of ownership by current or former employees,
contractors, designers or others and (ii) neither the Company nor
any of the Company Subsidiaries is materially infringing, diluting,
misappropriating or violating, nor has the Company or any or the
Company Subsidiaries received any written (or, to the knowledge of
the Company, oral) communications alleging that any of them has
materially infringed, diluted, misappropriated or violated, any of
the Proprietary Rights owned by any other person. Except as would
not, individually or in the aggregate, reasonably be
09533 1-
-10033-NY02.2690847.9-13-
expected to
have a Company Material Adverse Effect, to the Company’s
knowledge, no other person is infringing, diluting,
misappropriating or violating, nor has the Company or any or the
Company Subsidiaries sent any written communications since January
1, 2006 alleging that any person has infringed, diluted,
misappropriated or violated, any of the Proprietary Rights owned by
the Company and the Company Subsidiaries.
(v) Brokers
and Finders. No broker, finder or investment banker is entitled
to any
financial
advisory, brokerage, finder's or other fee or commission in
connection with this Agreement or the Warrant or the transactions
contemplated hereby or thereby based upon arrangements made by or
on behalf of the Company or any Company Subsidiary for which the
Investor could have any liability.
Article III
Covenants
3.1
Commercially Reasonable Efforts. Subject to the terms and
conditions of this
Agreement, each
of the parties will use its commercially reasonable efforts in good
faith to take, or cause to be taken, all actions, and to do, or
cause to be done, all things necessary, proper or desirable, or
advisable under applicable laws, so as to permit consummation of
the Purchase as promptly as practicable and otherwise to enable
consummation of the transactions contemplated hereby and shall use
commercially reasonable efforts to cooperate with the other party
to that end.
3.2
Expenses. Unless otherwise provided in this Agreement or the
Warrant, each of
the parties
hereto will bear and pay all costs and expenses incurred by it or
on its behalf in connection with the transactions contemplated
under this Agreement and the Warrant, including fees and expenses
of its own financial or other consultants, investment bankers,
accountants and counsel.
3.3
Sufficiency of Authorized Warrant Preferred Stock; Exchange
Listing.
(a) During the period
from the Closing Date until the date on which the Warrant has been
fully exercised, the Company shall at all times have reserved for
issuance, free of preemptive or similar rights, a sufficient number
of authorized and unissued Warrant Shares to effectuate such
exercise.
(b) If the Company
lists its Common Stock on any national securities exchange, the
Company shall, if requested by the Investor, promptly use its
reasonable best efforts to cause the Preferred Shares and Warrant
Shares to be approved for listing on a national securities exchange
as promptly as practicable following such request.
3.4 Certain
Notifications Until Closing. From the Signing Date until the
Closing, the
Company shall
promptly notify the Investor of (i) any fact, event or circumstance
of which it is aware and which would reasonably be expected to
cause any representation or warranty of the Company contained in
this Agreement to be untrue or inaccurate in any material respect
or to
09533 1-
-10033-NY02.2690847.9-13-
cause any
covenant or agreement of the Company contained in this Agreement
not to be complied with or satisfied in any material respect and
(ii) except as Previously Disclosed, any fact, circumstance, event,
change, occurrence, condition or development of which the Company
is aware and which, individually or in the aggregate, has had or
would reasonably be expected to have a Company Material Adverse
Effect; provided , however , that delivery of any
notice pursuant to this Section 3.4 shall not limit or affect any
rights of or remedies available to the Investor; provided ,
further , that a failure to comply with this Section 3.4
shall not constitute a breach of this Agreement or the failure of
any condition set forth in Section 1.2 to be satisfied unless the
underlying Company Material Adverse Effect or material breach would
independently result in the failure of a condition set forth in
Section 1.2 to be satisfied.
3.5 Access,
Information and Confidentiality.
(a) From the Signing
Date until the date when the Investor holds an amount of Preferred
Shares having an aggregate liquidation value of less than 10% of
the Purchase Price, the Company will permit the Investor and its
agents, consultants, contractors and advisors (x) acting through
the Appropriate Federal Banking Agency, or otherwise to the extent
necessary to evaluate, manage, or transfer its investment in the
Company, to examine the corporate books and make copies thereof and
to discuss the affairs, finances and accounts of the Company and
the Company Subsidiaries with the principal officers of the
Company, all upon reasonable notice and at such reasonable times
and as often as the Investor may reasonably request and (y) to
review any information material to the Investor’s investment
in the Company provided by the Company to its Appropriate Federal
Banking Agency. Any investigation pursuant to this Section 3.5
shall be conducted during normal business hours and in such manner
as not to interfere unreasonably with the conduct of the business
of the Company, and nothing herein shall require the Company or any
Company Subsidiary to disclose any information to the Investor to
the extent (i) prohibited by applicable law or regulation, or (ii)
that such disclosure would reasonably be expected to cause a
violation of any agreement to which the Company or any Company
Subsidiary is a party or would cause a risk of a loss of privilege
to the Company or any Company Subsidiary ( provided that the
Company shall use commercially reasonable efforts to make
appropriate substitute disclosure arrangements under circumstances
where the restrictions in this clause (ii) apply).
(b) From the Signing
Date until the date on which all of the Preferred Shares and
Warrant Shares have been redeemed in whole, the Company will
deliver, or will cause to be delivered, to the Investor:
(i)as soon as
available after the end of each fiscal year of the Company,
and
in any event
within 90 days thereafter, a consolidated balance sheet of the
Company as of the end of such fiscal year, and consolidated
statements of income, retained earnings and
cash flows of
the Company for such year, in each case prepared in accordance with
GAAP and setting forth in each case in comparative form the figures
for the previous fiscal year of the Company, and which shall be
audited to the extent audited financial statements are available;
and
09533
-0002-10033-NY02.2690847.9-15-
(ii)as soon as
available after the end of the first, second and third
quarterly
periods in each
fiscal year of the Company, a copy of any quarterly reports
provided to other stockholders of the Company or Company
management.
(c) The Investor will
use reasonable best efforts to hold, and will use reasonable best
efforts to cause its agents, consultants, contractors and advisors
to hold, in confidence all nonpublic records, books,
contracts, instruments, computer data and other data and
information (collectively, “ Information ”)
concerning the Company furnished or made available to it by the
Company or its representatives pursuant to this Agreement (except
to the extent that such information can be shown to have been (i)
previously known by such party on a non-confidential basis, (ii) in
the public domain through no fault of such party or (iii) later
lawfully acquired from other sources by the party to which it was
furnished (and without violation of any other confidentiality
obligation)); provided that nothing herein shall prevent the
Investor from disclosing any Information to the extent required by
applicable laws or regulations or by any subpoena or similar legal
process.
(d)
The Investor’s information
rights pursuant to Section 3.5(b) may be assigned by the Investor
to a transferee or assignee of the Purchased Securities or the
Warrant Shares or with a liquidation preference or, in the case of
the Warrant, the liquidation preference of the underlying shares of
Warrant Preferred Stock, no less than an amount equal to 2% of the
initial aggregate liquidation preference of the Preferred
Shares.
Article IV
Additional
Agreements
4.1 Purchase
for Investment. The Investor acknowledges that the Purchased
Securities
and the Warrant
Shares have not been registered under the Securities Act or under
any state securities laws. The Investor (a) is acquiring the
Purchased Securities pursuant to an exemption from registration
under the Securities Act solely for investment with no present
intention to distribute them to any person in violation of the
Securities Act or any applicable U.S. state securities laws, (b)
will not sell or otherwise dispose of any of the Purchased
Securities or the Warrant Shares, except in compliance with the
registration requirements or exemption provisions of the Securities
Act and any applicable U.S. state securities laws, and (c) has such
knowledge and experience in financial and business matters and in
investments of this type that it is capable of evaluating the
merits and risks of the Purchase and of making an informed
investment decision.
(a)The Investor
agrees that all certificates or other instruments representing
the
Warrant will
bear a legend substantially to the following effect:
“THE
SECURITIES REPRESENTED BY THIS INSTRUMENT HAVE NOT BEEN REGISTERED
UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR THE SECURITIES
LAWS OF ANY STATE AND MAY NOT BE TRANSFERRED, SOLD
09533
-0002-10033-NY02.2690847.9-15-
OR OTHERWISE
DISPOSED OF EXCEPT WHILE A REGISTRATION STATEMENT RELATING THERETO
IS IN EFFECT UNDER SUCH ACT AND APPLICABLE STATE SECURITIES LAWS OR
PURSUANT TO AN EXEMPTION FROM REGISTRATION UNDER SUCH ACT OR SUCH
LAWS.
THIS INSTRUMENT
IS ISSUED SUBJECT TO THE RESTRICTIONS ON TRANSFER AND OTHER
PROVISIONS OF A SECURITIES PURCHASE
AGREEMENT
BETWEEN THE ISSUER OF THESE SECURITIES AND THE INVESTOR REFERRED TO
THEREIN, A COPY OF WHICH IS ON FILE WITH THE ISSUER. THE SECURITIES
REPRESENTED BY THIS INSTRUMENT MAY NOT BE SOLD OR OTHERWISE
TRANSFERRED EXCEPT IN COMPLIANCE WITH SAID AGREEMENT. ANY SALE OR
OTHER TRANSFER NOT IN COMPLIANCE WITH SAID AGREEMENT WILL BE
VOID.”
(b)In addition,
the Investor agrees that all certificates or other
instruments
representing
the Preferred Shares and the Warrant Shares will bear a legend
substantially to the following effect:
“THE
SECURITIES REPRESENTED BY THIS INSTRUMENT ARE NOT SAVINGS ACCOUNTS,
DEPOSITS OR OTHER OBLIGATIONS OF A BANK AND ARE NOT INSURED BY THE
FEDERAL DEPOSIT INSURANCE CORPORATION OR ANY OTHER GOVERNMENTAL
AGENCY.
THE SECURITIES
REPRESENTED BY THIS INSTRUMENT HAVE NOT BEEN REGISTERED UNDER THE
SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES
ACT”), OR THE SECURITIES LAWS OF ANY STATE AND MAY NOT BE
TRANSFERRED, SOLD OR OTHERWISE DISPOSED OF EXCEPT WHILE A
REGISTRATION STATEMENT RELATING THERETO IS IN EFFECT UNDER SUCH ACT
AND APPLICABLE STATE SECURITIES LAWS OR PURSUANT TO AN EXEMPTION
FROM REGISTRATION UNDER SUCH ACT OR SUCH LAWS. EACH PURCHASER OF
THE SECURITIES REPRESENTED BY THIS INSTRUMENT IS NOTIFIED THAT THE
SELLER MAY BE RELYING ON THE EXEMPTION FROM SECTION 5 OF THE
SECURITIES ACT PROVIDED BY RULE 144A THEREUNDER. ANY TRANSFEREE OF
THE SECURITIES REPRESENTED BY THIS INSTRUMENT BY ITS ACCEPTANCE
HEREOF (1) REPRESENTS THAT IT IS A “QUALIFIED INSTITUTIONAL
BUYER” (AS DEFINED IN RULE 144A UNDER THE SECURITIES ACT),
(2) AGREES THAT IT WILL NOT OFFER, SELL
OR OTHERWISE
TRANSFER THE SECURITIES REPRESENTED BY THIS INSTRUMENT EXCEPT (A)
PURSUANT TO A REGISTRATION STATEMENT WHICH IS THEN EFFECTIVE UNDER
THE SECURITIES ACT, (B) FOR SO LONG AS THE SECURITIES REPRESENTED
BY THIS INSTRUMENT ARE ELIGIBLE FOR RESALE PURSUANT TO RULE 144A,
TO A PERSON IT REASONABLY BELIEVES IS A “QUALIFIED
INSTITUTIONAL BUYER” AS DEFINED IN RULE 144A UNDER THE
SECURITIES ACT THAT PURCHASES FOR ITS OWN ACCOUNT OR FOR THE
ACCOUNT OF A QUALIFIED INSTITUTIONAL BUYER
09533 1-
-10033-NY02.2690847.9-17-
TO WHOM NOTICE
IS GIVEN THAT THE TRANSFER IS BEING MADE IN RELIANCE ON RULE 144A,
(C) TO THE ISSUER OR (D) PURSUANT TO ANY OTHER AVAILABLE EXEMPTION
FROM THE REGISTRATION
REQUIREMENTS OF
THE SECURITIES ACT AND (3) AGREES THAT IT WILL GIVE TO EACH PERSON
TO WHOM THE SECURITIES REPRESENTED BY THIS INSTRUMENT ARE
TRANSFERRED A NOTICE SUBSTANTIALLY TO THE EFFECT OF THIS
LEGEND.
THIS INSTRUMENT
IS ISSUED SUBJECT TO THE RESTRICTIONS ON TRANSFER AND OTHER
PROVISIONS OF A SECURITIES PURCHASE
AGREEMENT
BETWEEN THE ISSUER OF THESE SECURITIES AND THE INVESTOR REFERRED TO
THEREIN, A COPY OF WHICH IS ON FILE WITH THE ISSUER. THE SECURITIES
REPRESENTED BY THIS INSTRUMENT MAY NOT BE SOLD OR OTHERWISE
TRANSFERRED EXCEPT IN COMPLIANCE WITH SAID AGREEMENT. ANY SALE OR
OTHER TRANSFER NOT IN COMPLIANCE WITH SAID AGREEMENT WILL BE
VOID.”
(c)In the event
that any Purchased Securities or Warrant Shares (i) become
registered
under the
Securities Act or (ii) are eligible to be transferred without
restriction in accordance with Rule 144 or another exemption from
registration under the Securities Act (other than Rule 144A), the
Company shall issue new certificates or other instruments
representing such Purchased Securities or Warrant Shares, which
shall not contain the applicable legends in Sections 4.2(a) and (b)
above; provided that the Investor surrenders to the Company
the previously issued certificates or other instruments.
4.3 Certain
Transactions. The Company will not merge or consolidate with,
or sell,
transfer or
lease all or substantially all of its property or assets to, any
other party unless the successor, transferee or lessee party (or
its ultimate parent entity), as the case may be (if not the
Company), expressly assumes the due and punctual performance and
observance of each and every covenant, agreement and condition of
this Agreement to be performed and observed by the
Company.
4.4 Transfer
of Purchased Securities and Warrant Shares; Restrictions on
Exercise of
the
Warrant. Subject to
compliance with applicable securities laws, the Investor shall be
permitted to transfer, sell, assign or otherwise dispose of
(“ Transfer ”) all or a portion of the Purchased
Securities or Warrant Shares at any time, and the Company shall
take all steps as may be reasonably requested by the Investor to
facilitate the Transfer of the Purchased Securities and the Warrant
Shares; provided that the Investor shall not Transfer any
Purchased Securities or Warrant Shares if such transfer would
require the Company to be subject to the periodic reporting
requirements of Section 13 or 15(d) of the Securities Exchange Act
of 1934 (the “ Exchange Act ”). In furtherance
of the foregoing, the Company shall provide reasonable cooperation
to facilitate any Transfers of the Purchased Securities or Warrant
Shares, including, as is reasonable under the circumstances, by
furnishing such information concerning the Company and its business
as a proposed transferee may reasonably request (including such
information as is required by Section 4.5(k)) and making management
of the Company
09533 1-
-10033-NY02.2690847.9-17-
reasonably
available to respond to questions of a proposed transferee in
accordance with customary practice, subject in all cases to the
proposed transferee agreeing to a customary confidentiality
agreement.
(a) Unless and until
the Company becomes subject to the reporting requirements of
Section 13 or 15(d) of the Exchange Act, the Company shall have no
obligation to comply with the provisions of this Section 4.5 (other
than Section 4.5(b)(iv)-(vi)); provided that the Company
covenants and agrees that it shall comply with this Section 4.5 as
soon as practicable after the date that it becomes subject to such
reporting requirements.
(i) Subject to the
terms and conditions of this Agreement, the Company covenants and
agrees that as promptly as practicable after the date that the
Company becomes subject to the reporting requirements of Section 13
or 15(d) of the Exchange Act (and in any event no later than 30
days thereafter), the Company shall prepare and file with the SEC a
Shelf Registration Statement covering all Registrable Securities
(or otherwise designate an existing Shelf Registration Statement
filed with the SEC to cover the Registrable Securities), and, to
the extent the Shelf Registration Statement has not theretofore
been declared effective or is not automatically effective upon such
filing, the Company shall use reasonable best efforts to cause such
Shelf Registration Statement to be declared or become effective and
to keep such Shelf Registration Statement continuously effective
and in compliance with the Securities Act and usable for resale of
such Registrable Securities for a period from the date of its
initial effectiveness until such time as there are no Registrable
Securities remaining (including by refiling such Shelf Registration
Statement (or a new Shelf Registration Statement) if the initial
Shelf Registration Statement expires). Notwithstanding the
foregoing, if the Company is not eligible to file a registration
statement on Form S-3, then the Company shall not be obligated to
file a Shelf Registration Statement unless and until requested to
do so in writing by the Investor.
(ii) Any registration
pursuant to Section 4.5(b)(i) shall be effected by means of a shelf
registration on an appropriate form under Rule 415 under the
Securities Act (a “ Shelf Registration Statement
”). If the Investor or any other Holder intends to distribute
any Registrable Securities by means of an underwritten offering it
shall promptly so advise the Company and the Company shall take all
reasonable steps to facilitate such distribution, including the
actions required pursuant to Section 4.5(d); provided that
the Company shall not be required to facilitate an underwritten
offering of Registrable Securities unless the expected gross
proceeds from such offering exceed (i) 2% of the initial aggregate
liquidation preference of the Preferred Shares if such initial
aggregate liquidation preference is less than $2 billion and (ii)
$200 million if the initial aggregate liquidation preference of the
Preferred Shares is equal to or greater than $2 billion. The lead
underwriters in any such distribution shall be selected by the
Holders of a majority
09533
-0002-10033-NY02.2690847.9-18-
of the
Registrable Securities to be distributed; provided that to
the extent appropriate and permitted under applicable law, such
Holders shall consider the qualifications of any broker-dealer
Affiliate of the Company in selecting the lead underwriters in any
such distribution.
(iii) The Company shall
not be required to effect a registration (including a resale of
Registrable Securities from an effective Shelf Registration
Statement) or an underwritten offering pursuant to Section 4.5(b):
(A) with respect to securities that are not Registrable Securities;
or (B) if the Company has notified the Investor and all other
Holders that in the good faith judgment of the Board of Directors,
it would be materially detrimental to the Company or its
securityholders for such registration or underwritten offering to
be effected at such time, in which event the Company shall have the
right to defer such registration for a period of not more than 45
days after receipt of the request of the Investor or any other
Holder; provided that such right to delay a registration or
underwritten offering shall be exercised by the Company (1) only if
the Company has generally exercised (or is concurrently exercising)
similar black-out rights against holders of similar securities that
have registration rights and (2) not more than three times in any
12-month period and not more than 90 days in the aggregate in any
12-month period.
(iv) If during any
period when an effective Shelf Registration Statement is not
available, the Company proposes to register any of its equity
securities, other than a registration pursuant to Section 4.5(b)(i)
or a Special Registration, and the registration form to be filed
may be used for the registration or qualification for distribution
of Registrable Securities, the Company will give prompt written
notice to the Investor and all other Holders of its intention to
effect such a registration (but in no event less than ten days
prior to the anticipated filing date) and will include in such
registration all Registrable Securities with respect to which the
Company has received written reques